Urothelial Carcinoma Bladder Clinical Trial
Official title:
Prospective Randomized Trial of Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer
This is a prospective randomized clinical trial in high risk urothelial bladder cancer to compare adjuvant radiotherapy versus observation after radical cyctectomy. This is to clarify the benefit of adjuvant radiotherapy while limiting gastrointestinal toxicities for patients with pathological high-risk bladder cancer through assessing locoregional control (LRC).
This is prospective randomized trial in high risk urothelial bladder cancer that includes 2 arms. The randomization will be done by permuted block method to 2 equal comparable groups. The total number of subjects will be 50 in each arm (Total=100 subjects). This study include patients who may receive neoadjuvant chemotherapy [Gemcitabine+Cisplatin]) or not. Arm (1) in this study (N=50) will received irradiation of both the bladder tumor bed and pelvic lymph nodes using IMRT technique. For Arm (2) (N=50) will undergo observation following radical cystectomy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03606174 -
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT05839119 -
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
|
Phase 1 | |
Completed |
NCT03558503 -
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT05136898 -
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
|
Phase 3 | |
Withdrawn |
NCT06090318 -
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
|
Phase 1/Phase 2 | |
Recruiting |
NCT03185468 -
Intervention of Bladder Cancer by CAR-T
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05243550 -
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05312671 -
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT02951325 -
Bladder Cancer Adjuvant Radiotherapy Trial
|
N/A | |
Recruiting |
NCT05375903 -
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1 | |
Recruiting |
NCT05401279 -
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04386746 -
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT06184516 -
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
|
Phase 2 | |
Not yet recruiting |
NCT05656235 -
Renal Retention in High Grade Upper Tract Urothelial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06331299 -
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Not yet recruiting |
NCT05037279 -
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
|
Phase 3 | |
Terminated |
NCT04688931 -
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05241340 -
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05077709 -
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
|
Phase 2 | |
Completed |
NCT04200963 -
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
|
Phase 1 |